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Abstract: Nanomaterials with unique characteristics exhibit favorable therapeutic and diagnostic properties,
implying their enormous potential as biomedical candidates. C60 has been used in gene- and drug-delivery, as
imaging agents, and as photosensitizers in cancer therapy. In this study, the inﬂuences of a cationic function-
alized fullerene on cellular behavior of human colorectal cancer cell line (HT-29) were investigated. Results
indicated that HT-29 treated with the studied compound showed a lower sensitivity but a signiﬁcant impair-
ment in migration and invasion by interfering with the activities of matrix metalloproteinases (MMP-2 and
9). The presence of fullerene also altered the capacity of adhesion-related proteins to perform their activity,
thereby inducing dramatically adverse eﬀects on the cell physiological functions such as cell adhesion. Thus,
our study suggests that this compound is a new potential anti-metastatic eﬀector and a therapeutic component
for malignant colorectal cancer.
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Introduction
Current status of anticancer chemotherapy of solid
malignant tumors indicates the necessity for agents ac-
tive against tumor metastases. Metastasis, the spread
of a primary tumor from its initial location to dis-
tant localities, is the main cause of death in cancer
patients. Colorectal cancer (CRC) can lead to metas-
tasization and represents one of the leading causes of
cancer-related mortality [1]. Its progression to a highly
advanced, metastatic stage (mCRC) still decreases the
overall 5-year survival to less than 8-10% [2].
The rapid development of nanotechnology and its ap-
plications has allowed for a wide variety of nanoparticles
to provide a broad range of opportunities in multidisci-
plinary ﬁelds and particularly in medicine, for clinical
therapy and diagnosis [3].
Recent reports show that carbon nanomaterials, in
particular fullerenes, inhibit various angiogenic sig-
nalling pathways and, therefore, can be potentially used
in anti-angiogenic therapy [4-7]. Based on these prop-
erties, we might expect that fullerenes can have sig-
niﬁcant eﬀects on tumour metastases either prevent-
ing their formation or inhibiting their growth. In this
context it might be interesting to note that the endohe-
dral metallofullerenol Gd@C82(OH)22 has been demon-
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strated to interfere with the neoplastic growth, as well
as with tumour metastasis, in a mouse cancer model,
with almost no toxicity to normal cells in vivo and in
vitro [8]. Also the water-soluble pristine (unmodiﬁed)
C60 inhibits the transplantable malignant Lewis lung
carcinoma growth and metastasis in C57Bl/6J male
mice [7]. Limited knowledge exists on the capacity of
the fullerenes to interfere with tumor invasion and the
mechanism involved in the fullerene anti-metastatic ef-
fect remains to be elucidated. To explore this further,
the eﬀect of fullerene on key steps of tumor metasta-
sis, including cell adhesion, migration and invasion, was
investigated.
Our previous studies demonstrated that a cationic
fullerene derivative (C60+), a fulleropyrrolidinium salt,
was able to eﬀectively inhibit tumor cell proliferation
in vitro [9] and, recently published data from our lab-
oratory, obtained by RNA-sequencing on MCF7 cells
[10], indicated that the expression proﬁle of several pro-
teins involved in cell-cell adherence junctions was al-
tered when treated by C60+. Therefore, the question if
compound C60+ plays a role in the regulation of migra-
tion and adhesion of HT-29 colorectal cell line naturally
arose.
The present study examined the hypothesis that
derivative C60+ participates in colorectal cancer cell
invasion. Cells treated with it exhibited signiﬁcant im-
pairment in a series of preliminary migration and adhe-
sion assays in vitro. Thus, compound C60+ may be a
new potential anti-tumor eﬀector and therapeutic com-
ponent for malignant colorectal cancer.
Experimental
The synthesis and the characterization of the
fullerene derivative C60+ was performed as previously
described [9,11].
The human colorectal carcinoma cell line were pur-
chased from the ECACC N◦ 86012803 (HT-29). HT-
29 was maintained in RPMI-1640. The culture
medium was supplemented with 10% (v/v) fetal bovine
serum (FBS), penicillin (100 U/mL), streptomycin (100
μg/mL), and L-glutamine 2 mM; cells were grown at
37◦C in a 95% air and 5% CO2 humidiﬁed incubator.
HT-29 were harvested by trypsinization and plated
into 96-well culture plates at approximately 1.5 × 104
per well. After incubated for 24 h, diﬀerent concen-
trations of C60+ (1, 5, 10, 25 and 40 μM) dissolved
in culture medium were added to each well. Then the
samples were incubated 48 h at 37◦C in the humid-
iﬁed atmosphere (5% CO2). The colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay was performed to assess the metabolic ac-
tivity of cells treated as described above. 20 μl stock
MTT (5 mg/mL) were added to each well, and cells
were then incubated for 4 h at 37◦C. Cells were lysed
with isopropanol HCl 0.04 N. Absorbance was measured
at 540 and 630 nm using a microplate reader (Auto-
mated Microplate Reader EL311, BIOTEK® Instru-
ments, Vermont, USA). All measurements were done
in six replicates, and at least three independent exper-
iments were carried out.
A 96-well plate was pre-coated with ﬁbronectin, col-
lagen I, collagen IV, Poly-L-lysine, laminin (Sigma-
Aldrich, St. Louis, USA) and Matrigel™ (20 μg/ml) for
4 h at 37◦C or 4◦C overnight and subsequently blocked
with PBS-BSA 0.1% (w/v) for 15 min at 37◦C. Sub
conﬂuent tumor cells were treated with C60+ (25 μM)
for 48 h and then grown in serum-free medium for addi-
tional 24 h. Cells were trypsinized with 1 mM EDTA,
resuspended in serum free medium with 0.1% BSA for
30 min at room temperature to ensure re-expression
of integrins on the cell surface and seeded in the plate
(5 × 104 cells/well). HT-29 were allowed to attach to
each substrate for 1 h at 37◦C and subsequently ﬁxed
with trichloroacetic acid 10% (v/v) for 1 h at 4◦C and
stained with sulphorodamine B 0.4% (w/v). The ab-
sorbance was read at 570 nm and related to the adhe-
sion rate.
Eﬀects of the C60+ to inhibit cancer cells motility
were tested performing a conventional Boyden cham-
ber assay.
HT-29 cells, sown 72 h before, were left in serum-free
medium containing 0.1% bovine serum albumin (BSA)
for 24 h after being treated with C60+ (25 μM) for 48 h,
at 37◦C. At the end of the treatment, 5×104 cells were
sown in 200 μL of serum-free medium containing 0.1%
BSA, in the upper side of a polyvinylpirrolidone-free
polycarbonate ﬁlter (6.5-mm diameter and 8-μm pore
size) set in a Transwell® cell culture chamber (Corn-
ing Costar Italia, Milan, Italy) in triplicate. The lower
compartment was ﬁlled with the appropriate culture
medium, supplemented with 10% FBS. Plates were left
in the incubator for 72 h, at 37◦C, 5% CO2, 100% rel-
ative humidity. At the end of the incubation, cells that
had not invaded were mechanically removed from the
upper surface of the ﬁlter by wiping them with a cot-
ton bud. Cells that had migrated to the lower surface
were ﬁxed with 1.1% glutaraldehyde for 15 min, washed
with deionised water and air-dried. Transwells® were
then stained with 0.1% crystal violet in 200 mM bo-
rate buﬀer, pH 9.0 for 20 min at room temperature.
After washings with deionised water and complete dry-
ing, the dye was dissolved in 10% acetic acid and the
absorbance was read at 590 nm by a SpectraCount spec-
trophotometer (Packard Bell, Meriden, CT, USA).
Invasive capability was measured in a Transwell®
cell culture chamber (Corning Costar Italia, Milan,
Italy) according to a method modiﬁed from Albini et al.
[12]. In brief, the surface of a polyvinylpirrolidone-free
polycarbonate ﬁlter (6.5-mm diameter and 8-μm pore
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size) was coated with 30 μg per 50 μL of Matrigel®
(Beckton Dickinson, Bedford, MA, USA) diluted in
DMEM and air-dried overnight at room temperature.
The ﬁlters were reconstituted with DMEM immediately
before use. HT-29 cells, sown 72 h before, were left in
serum-free medium containing 0.1% bovine serum al-
bumin (BSA) for 24 h after to being treated with C60+
(25 μM) for 48 h, at 37◦C. At the end of the treatment,
cells were harvested with trypsin–EDTA, and 5 × 104
cells were sown in 200 μL of serum-free medium contain-
ing 0.1% BSA, in the upper compartment chamber, in
triplicate. The lower compartment was ﬁlled with the
appropriate culture medium, supplemented with 10%
FBS. Plates were left in the incubator for 96 h, at 37◦C,
5% CO2, 100% relative humidity. At the end of the in-
cubation, the plate was processed as described in the
migration assay.
To perform gelatin zymography, supernatant was col-
lected from sub conﬂuent cell culture treated for 48 h
with C60+ and left 24 h in serum-free medium. Pro-
teins present in the supernatant were concentrated by
centrifugation and quantiﬁed using Nano Drop spec-
trophotometer. 180 μg of total mixture of proteins
were separated on 10% polyacrylamide gel containing
0.06% gelatin (Sigma-Aldrich, St. Louis, USA). Then
the gel was washed for 30 minutes using 2.5% Triton X-
100 solution to remove SDS and then incubated in an
activating buﬀer (50 mm pH 7.5 TRIS, 5 mM CaCl2,
0.2 M NaCl) for 20 h at 37◦C. Gelatinase activity was
demonstrated by gel staining with 0.5% Commasie blue
and destaining with 30% methanol solution and 10%
acetic acid. To assess activity, the stained gel was pho-
tographed and analyzed using ImageJ software.
Data were subjected to computer-assisted analysis by
Graph Pad Instat 3 and statistical signiﬁcance or re-
gression analysis, were reported in the text.
Results and discussion
Fullerene derivative C60+ inhibited HT-29 pro-
liferation
The eﬀects of C60+ (Fig. 1(a)) on the viability of HT-
29 cells after 48 h challenge with concentrations rang-
ing from 1 to 40 μM are reported in Fig. 1(b). C60+
caused a statistically signiﬁcant reduction of cell viabil-
ity (about 40% inhibition), as determined by the MTT
test only at the highest dose tested, being the other
dosages only marginally capable to inﬂuence HT-29 cell
growth during the experiment. This result is consistent
with unpublished data showing diﬀerent degrees of cy-
totoxicity of this fullerene derivative in vitro on a num-
ber of tumor cell lines: MCF7 cells were particularly
sensitive to the cytotoxic eﬀects [9], whereas other cell
lines, e.g. MDA-MB231, were much less sensitive, as re-
ported here for HT-29 cells. The scenario depicted by
our RNA-seq analysis suggested that C60+ induced an
alteration of the gene expression targeting mTOR sig-
naling at diﬀerent levels in MCF7 cell line [10]. Among
the many factors potentially determining an inhibition
of mTOR signaling, we proposed a decrease of avail-
able cellular energy as the most plausible. We here
hypothesize that the mechanism of action of C60+ in
the HT-29 cell line could be the same, given that HT-29
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Fig. 1 (a) Chemical structure of fullerene derivative C60+;
(b) Eﬀect of C60+ on proliferation of Colon Cancer Cell
Line (HT-29). The cells were treated for 48 h at diﬀerent
concentrations. Each value represent the mean of 3 separate
experiments, each with at least three independent samples,
± S.D. (***) p < 0.01
Cell adhesion analysis
Cell adhesion to the extracellular matrix (ECM) is
an important step that regulates diﬀerent cellular func-
tions including cell migration and proliferation, diﬀer-
entiation, and tissue organization [13]. This event is
mediated by cell surface receptors, the integrins, α and
β chain heterodimers with short cytoplasmic tails, the
enzymatic activity of which activates a variety of intra-
cellular signalling pathways [14]. Integrins were shown
to be involved in the processes of cancer cell invasion
and metastasis [15], and, most notably, the integrin-
ECM interactions were also demonstrated to have a
role for cell survival and resistance to chemotherapy
in many types of solid cancers, including colon cancer
[16].
In order to mimic the detachment of metastatic cells
from the primary mass and their adhesion in a sec-
ondary site, we performed a study where HT-29 cells
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were exposed to C60+ at 25 μM for 48 h, then har-
vested from the plate and allowed to adhere to diﬀerent
substrates components of the ECM such as laminin, ﬁ-
bronectin and collagens. Data reported in Table 1 show
that C60+ causes a similar inhibition of the adherence
ability of HT-29 cells independently whether the sub-
strate used was a component of the ECM, an unspeciﬁc
substrate (poly-L-lysine) or no substrate at all. How-
ever, in all the cases, the HT-29 cells, after such treat-
ment, showed a marked reduction (60-70% inhibition)
of their ability to adhere as compared to untreated cells.
Table 1 Inhibitory potential of C60+ to the interac-
tion between HT-29-ECM substrates. After treat-
ment with C60+, cells were seeded on 96-well plate
functionalized with ﬁbronectin, collagen I and IV,
laminin, poly-L-lysine and Matrigel (20 μg/mL) and
left to adhere 1 h at 37◦C with 5% CO2. Unbound
cells were removed while adhered cells were ﬁxed,
stained with sulphorodamine B and absorbance read
at 570 nm. Results obtained for each substrate are
expressed as percentage of adhesion inhibition of
treated HT-29, considering the untreated HT-29 ad-
hesion value as 100%







This eﬀect might be related to a number of hy-
potheses. Integrins might be activated by extracellu-
lar events, aside from the intracellular signaling events
[17], such as ligand binding, divalent cation concentra-
tion, mechanical stress, all of them potentially pertur-
bated by the fullerene treatment. However it must be
taken into account also the possible eﬀect of this com-
pound on cell viability that, although not leading to
cell death, might keep the treated cells to a lower stage
of “biological activity”.
Cell migration, invasion and zymography assays
Migration and invasion are two essential steps of
the pathological events leading to cancer metastasis.
We studied cell migration using a conventional Boyden
chamber assay (Fig. 2(a)).
HT-29 cells, treated with C60+ for 48 h, were left to
migrate for 72 h from the upper chamber through the
insert, following the chemotactic signal (serum) com-
ing from the lower side of the chamber. Data reported
in Fig. 2(a) shows a pronounced (80%) and statisti-
cally signiﬁcant reduction of the migration ability of
the treated cells as compared to control constituted by
untreated HT-29 cells.
Similar eﬀects were obtained when we studied the in-
vasion process. In this case, cells were seeded on a layer
of matrigel previously deposed on the Boyden chamber
grid and evaluated after 96 h. Compound C60+ inhib-
ited more than 75% the capacity of the treated HT-29
cells to cross the matrigel barrier and to accumulate in




















































Fig. 2 (a) Boyden chamber assay: HT-29 cells were treated
with C60+ for 48 h and then seeded in a Boyden chamber
and left to migrate for 72 h. At the end of this time, cells
that migrated were ﬁxed, stained with crystal violet and the
absorbance read at 590 nm. Statistical analysis was per-
formed with ANOVA Unpaired t test-One tail t test (∗ ∗ ∗)
p < 0.0001 vs control (HT-29). (b) Invasion assay: HT-
29 treated 48 h with C60+ were seeded on the upper side
of inserts functionalized with matrigel and were left invade
96 h. At the end of incubation, cells on the lower side of
the inserts were ﬁxed, stained with crystal violet and the
absorbance read. Statistical analysis was performed with
ANOVA Unpaired t test-One tail t test (∗ ∗ ∗) p < 0.0001
vs HT-29.
The compared analysis of the eﬀects of C60+ on mi-
gration and invasion suggests that this compound does
not reduce the capacity of HT-29 cells to degrade the
ECM. In fact, it seems that the eﬀects of the consid-
ered fullerene derivative on these cells might consist of a
more general reduction of the cells ability to move or a
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reduced capacity to respond to the chemotactic signal,
operated by the serum present in the lower wall. On the
contrary, the treated cells have a reduced gelatinolytic
ability, as shown by a study of MMP2 and MMP9 ac-
tivity, performed on the supernatant obtained by the
HT-29 cells exposed to C60+ at 25 μM for 48 h (38-
42% inhibition, Fig. 3), suggesting that the treated cells





Fig. 3 Gelatinolytic activity of MMP-2 and MMP-9 was
evaluated in HT-29 cells treated with C60+ at 48 h.
The activation of the zymogen form of MMP2 (pro-
MMP2) is a cell-surface event that is mediated by mem-
bers of the membrane-type (MT) subfamily of MMPs
as MT1-MMP and by the tissue inhibitor of metallopro-
teinase (TIMP-2), a member of the family of MMP in-
hibitors [18,19]. It has been demonstrated that this in-
hibitor directly interacts with MMP2 or through MT1-
MMP/TIMP-2 complex formation reducing the enzy-
matic activity of MMP2 [20-22].
Recently we found that C60+ increases 4-folds the ex-
pression level of TIMP-2 after 24 and 48 h of treatment
[10] in the human breast cancer cell line MCF7. This
result could suggest a similar eﬀect of this compound
also on HT-29 colon cancer cell line and a consequent
reduced gelatinolytic activity of MMP2 detected after
treatment of cells with fullerene C60+.
Moreover the complex pro-MMP2 and TIMP-2 is
able to inhibit other MMPs such as MMP9 through
the formation of a ternary complex pro-MMP2-TIMP-
2-MMP9 [23-25]. This data suggest that the reduced
MMP9 activity detected in treated HT-29 cells, could
be due to the increased level of TIMP-2 after C60+
treatment and its modulation on MMP9 activity via
MMP2 involvement.
Conclusions
The in vitro study of fullerene derivative C60+ on the
ability of HT-29 cells to migrate and invade, events that
mimic important steps of the process of metastasis for-
mation, showed promising eﬀects. The compound, in
fact, inhibited the capacity of HT-29 cells to re-adhere,
to migrate and to invade and these eﬀects were, at least
in part, associated with the decrease of the gelatinolytic
activity of the treated cells. The treated HT-29 cells
did not present signiﬁcant diﬀerences in the adherence
process in presence of the various ECM substrates and
this seems to rule out an eﬀect of C60+ on cell inte-
grins. Rather, it seems that C60+ might act on a more
generalized pathway responsible for multiple eﬀects of
the metastatic capacity of the cells.
Anyhow, these data, although preliminarily and con-
sidering the role attributed to phenomena such as ad-
hesion and migration for the process of metastasis for-
mation suggest the ability of this fullerene derivative to
interfere with metastases of solid tumors, in agreement
with other data already reported in the literatures [7,8].
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